Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 3/20 | 0.55 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.55 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.55 |
| ▸ | CA1 | P00915 | 3/20 | 0.55 |
| ▸ | CA2 | P00918 | 3/20 | 0.55 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | TPMT | P51580 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | WDR5 | P61964 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 5/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ACLY | P53396 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8763536 | 0.80 | CA1 (0.50) | AKR1C3AKR1C2AKR1C1CA1CA2 | |
| SCHEMBL3524890 | 0.80 | AKR1C4 (0.63) | AKR1C3AKR1C2AKR1C1CA1CA2 | |
| SCHEMBL4862551 | 0.80 | AKR1C2 (0.69) | AKR1C3AKR1C2AKR1C1CA1CA2 | |
| SCHEMBL8820653 | 0.80 | CYP3A4 (0.61) | AKR1C3AKR1C2AKR1C1CA1CA2 | |
| SCHEMBL22492699 | 0.79 | ABL1 (0.45) | CA1CA2ALDH1A1HPGDHSD17B10 | |
| SCHEMBL21821500 | 0.78 | CA1 (0.54) | AKR1C3AKR1C2AKR1C1CA1CA2 | |
| SCHEMBL21583494 | 0.78 | HSD17B10 (0.50) | ALDH1A1HPGDHSD17B10CYP3A4TSHR | |
| SCHEMBL8346094 | 0.77 | TSHR (0.45) | AKR1C3AKR1C2AKR1C1CA1CA2 | |
| SCHEMBL23529333 | 0.77 | ALDH1A1 (0.48) | AKR1C3AKR1C2AKR1C1CA1CA2 | |
| SCHEMBL2950898 | 0.77 | CYP3A4 (0.57) | AKR1C3AKR1C2AKR1C1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092076-A1 | NOVEL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4695243-A1 | NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2026-02-18 | — | — | EP | disclosed |
| WO-2024213552-A1 | NLRP3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092076-A1 | NOVEL COMPOUNDS | NOD1, NLRP3, ARRB1 | AKR1C3 184/4885AKR1C2 561/4885AKR1C1 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.